ARV tender cut by more than half

2010-12-14 14:06

The latest tender for the government’s rollout of antiretroviral drugs was 53% cheaper than previously, even though the same 10 companies were awarded the contract, Health Minister Aaron Motsoaledi announced in Pretoria today.

Motsoaledi conceded the government might have “made a mistake” when awarding the two-year tenders previously.

He said that instead of paying in excess of R8.8 billion for ARVs, the government would only be paying R4.8 billion over the next two years starting in January next year.

This represented a R4.7-billion saving over what the government had previously paid for rolling out the drugs.

“South Africa can now afford to treat twice as many people with the same amount of money,” Motsoaledi said.

“It is notable that these tender price reductions have been achieved through the same suppliers that are contracted in the current tender.”

The minister said the 10 companies are Abbott, Adcock, Aurobindo, Cipla Medpro, MSD, Pharmacare, Sonke, Specpharm and Strides.

Asked why the same suppliers were able to provide ARVs at a lower cost, he replied: “Perhaps it was our mistake in government, perhaps we were sleeping.”

He said he was not at this stage contemplating a “witch hunt” of suppliers because of the higher prices previously paid.

Some of the suppliers had claimed that at lower prices there would be substantial job losses, he said.

“I called their bluff. There are more profits in pharmaceuticals than in oil. My message to pharmaceuticals is that they are in a sector that is very sensitive. They mustn’t fish from our troubled waters.”

He said government hoped to replicate the success of cutting the cost of procuring ARVs when it focused on the tender process for tuberculosis drugs, vaccines and drugs for the treatment of diseases related to maternal and child health.

He said that of the 4.8 million people tested in South Africa since World Aids Day on December 1, at total of 905 000 (18%) were found to be HIV positive.

Highlighting the price differential in the ARV drugs, he said that 600mg of Efavirenz in tablet form cost the government R107.07 in 2008 when the previous tender was awarded.

Under the new tender it would cost R39.22, which is 63% lower.

Another drug, 150mg of Lamivudine in tablet form cost the government R29.77 in 2008.

It would now cost the government R18.22, a 39% drop in price.

A 200mg dose of Nevirapine tablets cost R31.53 in 2008. It would now cost R22.99, or 27% less.

There was a 65% drop in the price of 300mg of Tenofovir tablets from R155.60 to R54.82.

Comment could not immediately be obtained from the National Association of Pharmaceutical Manufacturers.

Join the conversation! encourages commentary submitted via MyNews24. Contributions of 200 words or more will be considered for publication.

We reserve editorial discretion to decide what will be published.
Read our comments policy for guidelines on contributions. publishes all comments posted on articles provided that they adhere to our Comments Policy. Should you wish to report a comment for editorial review, please do so by clicking the 'Report Comment' button to the right of each comment.

Comment on this story
Comments have been closed for this article.

Inside News24

Traffic Alerts
There are new stories on the homepage. Click here to see them.


Create Profile

Creating your profile will enable you to submit photos and stories to get published on News24.

Please provide a username for your profile page:

This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire network.


Location Settings

News24 allows you to edit the display of certain components based on a location. If you wish to personalise the page based on your preferences, please select a location for each component and click "Submit" in order for the changes to take affect.

Facebook Sign-In

Hi News addict,

Join the News24 Community to be involved in breaking the news.

Log in with Facebook to comment and personalise news, weather and listings.